The American Academy of Orthopaedic Surgeons on Oct. 15 introduced the AAOS Biologics Dashboard to help physicians keep up to date with the approval status of biologic innovations.
A Wisconsin stem cell clinic has been cautioned by the FDA for marketing intrathecal and intravenous injections of human stem cell and tissue-based products for a variety of neurologic conditions, according to the Regulatory Affairs Professionals Society.
Richmond, Va.-based VCU Health spine surgeon Rick Placide, MD, implanted the first Signafuse strips in a patient during a posterolateral lumbar fusion, according to a Sept. 2 news release.
A number of emerging biologic technologies are currently being evaluated and launched in the spine field. Here are six key developments in the past month:
Orthobiologics company Kuros Biosciences has treated the first patient in its clinical trial evaluating Fibrin-PTH for transforaminal lumbar interbody fusion in patients with degenerative disc disease.
The Steadman Philippon Research Institute in Vail, Colo., has received a grant from the National Institutes of Health to study the use of bone marrow stem cells to delay osteoarthritis in the knee.
The FDA has cleared Genentech's Evrysdi drug for spinal muscular atrophy in adults and children 2 months of age and older, according to an Aug. 10 announcement.
Since the beginning of the year, Becker's Spine Review has reported on eight orthobiologic and regenerative medicine companies that have launched new products, received FDA clearances and demonstrated favorable outcomes in clinical trials:
Orthobiologics company Bioventus said July 16 that it has invested $15 million in CartiHeal and agreed on an option structure to acquire the company pending approval of its Agili-C implant.
The Becker's Spine Review website uses cookies to display relevant ads and to enhance your browsing experience. By continuing to use our site, you acknowledge that you have read, that you understand, and that you accept our Cookie Policy and our Privacy Policy.
